{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:28:20Z","timestamp":1792290500646,"version":"4.4.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP 1088455"],"award-info":[{"award-number":["APP 1088455"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["848015014"],"award-info":[{"award-number":["848015014"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["255"],"award-info":[{"award-number":["255"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["149"],"award-info":[{"award-number":["149"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["331"],"award-info":[{"award-number":["331"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["154"],"award-info":[{"award-number":["154"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["268"],"award-info":[{"award-number":["268"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["152"],"award-info":[{"award-number":["152"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["179"],"award-info":[{"award-number":["179"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ahj.2019.09.011","type":"journal-article","created":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T17:06:47Z","timestamp":1571591207000},"page":"46-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"special_numbering":"C","title":["The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics"],"prefix":"10.1016","volume":"218","author":[{"given":"Stefan M","family":"Nidorf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aernoud T. L","family":"Fiolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W","family":"Eikelboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Schut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjerk S. J","family":"Opstal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem A","family":"Bax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charley A","family":"Budgeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan G. P","family":"Tijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arend","family":"Mosterd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H","family":"Cornel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ahj.2019.09.011_bb0005","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S2213-8587(17)30327-3","article-title":"Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label","volume":"5","author":"Ueki","year":"2017","journal-title":"randomised controlled trial Lancet Diabetes Endocrinol"},{"issue":"25","key":"10.1016\/j.ahj.2019.09.011_bb0010","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2019.09.011_bb0015","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u20131681. doi:https:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"10.1016\/j.ahj.2019.09.011_bb0020","first-page":"1","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ahj.2019.09.011_bb0025","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1611179","article-title":"Effect of intensive blood-pressure treatment on patient-reported outcomes","volume":"377","author":"Berlowitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ahj.2019.09.011_bb0030","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-Year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Bethel","year":"2008","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ahj.2019.09.011_bb0035","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2019.09.011_bb0040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.molimm.2016.09.019","article-title":"Complement activation by cholesterol crystals triggers a subsequent cytokine response","volume":"84","author":"Niyonzima","year":"2017","journal-title":"Mol Immunol"},{"issue":"7293","key":"10.1016\/j.ahj.2019.09.011_bb0045","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.ahj.2019.09.011_bb0050","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMra1601611","article-title":"Crystallopathies","volume":"374","author":"Mulay","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ahj.2019.09.011_bb0055","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jcmg.2017.08.013","article-title":"Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: A CT coronary angiography study","volume":"11","author":"Vaidya","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"issue":"12","key":"10.1016\/j.ahj.2019.09.011_bb0060","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ahj.2019.09.011_bb0065","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1172\/JCI118147","article-title":"Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils","volume":"96","author":"Cronstein","year":"1995","journal-title":"J Clin Invest"},{"issue":"21","key":"10.1016\/j.ahj.2019.09.011_bb0070","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMra1216063","article-title":"Mechanisms of acute coronary syndromes and their implications for therapy","volume":"368","author":"Libby","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ahj.2019.09.011_bb0075","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1161\/CIRCRESAHA.114.302699","article-title":"Inflammation and its resolution as determinants of acute coronary syndromes","volume":"114","author":"Libby","year":"2014","journal-title":"Circ Res"},{"issue":"10","key":"10.1016\/j.ahj.2019.09.011_bb0080","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.clinthera.2014.07.017","article-title":"Mechanism of action of colchicine in the treatment of gout","volume":"36","author":"Dalbeth","year":"2014","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.ahj.2019.09.011_bb0085","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine-update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ahj.2019.09.011_bb0090","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/path.4116","article-title":"Inflammasomes in wound healing and fibrosis","volume":"229","author":"Artlett","year":"2013","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.ahj.2019.09.011_bb0095","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s10753-015-0237-7","article-title":"Effect of colchicine on platelet-platelet and platelet-leukocyte interactions: a pilot study in healthy subjects","volume":"39","author":"Shah","year":"2016","journal-title":"Inflammation"},{"issue":"18","key":"10.1016\/j.ahj.2019.09.011_bb0100","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJM197410312911803","article-title":"A controlled trial of colchicine in preventing attacks of familial Mediterranean fever","volume":"291","author":"Zemer","year":"1974","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ahj.2019.09.011_bb0105","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.2165\/11205470-000000000-00000","article-title":"Oral colchicine (Colcrys\u00ae)","volume":"70","author":"Yang","year":"2010","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.ahj.2019.09.011_bb0110","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: Twenty-four\u2013hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ahj.2019.09.011_bb0115","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.arcmed.2015.01.004","article-title":"Colchicine reduces restenosis after balloon angioplasty treatment for in-stent restenosis","volume":"46","author":"Kong","year":"2015","journal-title":"Arch Med Res"},{"issue":"96","key":"10.1016\/j.ahj.2019.09.011_bb0120","article-title":"Colchicine in cardiac disease: A systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Verma","year":"2015","journal-title":"BMC Cardiovasc Disord"},{"issue":"3","key":"10.1016\/j.ahj.2019.09.011_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011047","article-title":"Colchicine for prevention of cardiovascular events","volume":"2014","author":"Hemkens","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.ahj.2019.09.011_bb0130","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3899\/jrheum.111533","article-title":"Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout","volume":"39","author":"Crittenden","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ahj.2019.09.011_bb0135","series-title":"Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims","author":"Solomon","year":"2015"},{"issue":"16","key":"10.1016\/j.ahj.2019.09.011_bb0140","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.jacc.2013.01.055","article-title":"Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients","volume":"61","author":"Deftereos","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.ahj.2019.09.011_bb0145","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002128","article-title":"Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome","volume":"4","author":"Martinez","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.ahj.2019.09.011_bb0150","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.09.011_bb0155","doi-asserted-by":"crossref","unstructured":"Harada M, Van Wagoner DR NS. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J 2015;79(3):495\u2013502. doi:https:\/\/doi.org\/10.1253\/circj.CJ-15-0138. Epub 2015 Feb 16","DOI":"10.1253\/circj.CJ-15-0138"},{"issue":"21","key":"10.1016\/j.ahj.2019.09.011_bb0160","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1161\/CIRCULATIONAHA.111.026153","article-title":"Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy","volume":"124","author":"Imazio","year":"2011","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ahj.2019.09.011_bb0165","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/MED.0b013e32833bf6dc","article-title":"Role of IL-1beta in type 2 diabetes","volume":"17","author":"Dinarello","year":"2010","journal-title":"Curr Opin Endocrinol Obes"},{"issue":"142","key":"10.1016\/j.ahj.2019.09.011_bb0170","article-title":"The role of inflammation in venous thromboembolism","volume":"6","author":"Branchford","year":"2018","journal-title":"Front Pediatr"},{"issue":"17","key":"10.1016\/j.ahj.2019.09.011_bb0175","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2019.09.011_bb0180","doi-asserted-by":"crossref","unstructured":"Hicks KA, Tcheng JE, Bozkurt B, et al. 2014 ACC\/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials. J Am Coll Cardiol. 2015;66(4):403\u2013469. doi:10.1016\/j.jacc.2014.12.018","DOI":"10.1016\/j.jacc.2014.12.018"},{"issue":"16","key":"10.1016\/j.ahj.2019.09.011_bb0185","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","article-title":"Third universal definition of myocardial infarction","volume":"60","author":"Thygesen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.09.011_bb0190","unstructured":"ICH. ICH Harmonised Tripartite Guideline\u2014Statistical Principles For Clinical Trials; 1998."},{"key":"10.1016\/j.ahj.2019.09.011_bb0195","unstructured":"World Health Organisation (WHO). Top 10 causes of death worldwide. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death. Published 2018. Accessed March 10, 2019."},{"key":"10.1016\/j.ahj.2019.09.011_bb0200","unstructured":"Withdrawal of the Marketing Authorisation Application for Canakinumab Novartis (Canakinumab). London; 2018. https:\/\/www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-answers-withdrawal-marketing-authorisation-application-canakinumab-novartis-canakinumab_en.pdf. Accessed March 30, 2019."},{"issue":"25","key":"10.1016\/j.ahj.2019.09.011_bb0205","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/eurheartj\/ehv653","article-title":"Cholesterol crystal induced arterial inflammation and destabilization of atherosclerotic plaque","volume":"37","author":"Janoudi","year":"2016","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ahj.2019.09.011_bb0210","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clinthera.2018.11.016","article-title":"Why colchicine should be considered for secondary prevention of atherosclerosis: an overview","volume":"41","author":"Nidorf","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.ahj.2019.09.011_bb0215","doi-asserted-by":"crossref","unstructured":"Hentgen V, Grateau G, Kone-Paut I, et al. Evidence-based recommendations for the practical management of Familial Mediterranean Fever. In: Seminars in Arthritis and Rheumatism. Vol 43. Elsevier; 2013:387\u2013391. doi:https:\/\/doi.org\/10.1136\/annrheumdis-2014-206844","DOI":"10.1016\/j.semarthrit.2013.04.011"},{"issue":"8","key":"10.1016\/j.ahj.2019.09.011_bb0220","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ahj.2019.09.011_bb0225","doi-asserted-by":"crossref","unstructured":"Demidowich AP, Levine JA, Onyekaba GI, et al. Effects of colchicine in adults with metabolic syndrome: A pilot randomized controlled trial. Diabetes, Obes Metab. 2019;21(7):dom.13702. doi:https:\/\/doi.org\/10.1111\/dom.13702","DOI":"10.1111\/dom.13702"},{"issue":"10","key":"10.1016\/j.ahj.2019.09.011_bb0230","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/jama.2014.11026","article-title":"Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial","volume":"312","author":"Imazio","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2019.09.011_bb0235","unstructured":"U.S. Food & Drug Administration. Postmarket Drug Safety Information for Patients and Providers - Colchicine (marketed as Colcrys) Information. June 30."},{"issue":"3","key":"10.1016\/j.ahj.2019.09.011_bb0240","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/431592","article-title":"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study","volume":"41","author":"Hung","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.ahj.2019.09.011_bb0245","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1097\/MJT.0b013e31825a364a","article-title":"Colchicine toxicity in end-stage renal disease patients","volume":"21","author":"Solak","year":"2014","journal-title":"Am J Ther"},{"key":"10.1016\/j.ahj.2019.09.011_bb0250","doi-asserted-by":"crossref","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431\u20131446. doi:https:\/\/doi.org\/10.1002\/acr.21772.","DOI":"10.1002\/acr.21772"},{"issue":"12","key":"10.1016\/j.ahj.2019.09.011_bb0255","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1592\/phco.24.17.1784.52334","article-title":"Colchicine myotoxicity: case reports and literature review","volume":"24","author":"Wilbur","year":"2004","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"issue":"7\u20138","key":"10.1016\/j.ahj.2019.09.011_bb0260","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1345\/aph.1H064","article-title":"Rhabdomyolysis in a patient treated with colchicine and atorvastatin","volume":"40","author":"Tufan","year":"2006","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.ahj.2019.09.011_bb0265","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/mus.20135","article-title":"Cytoskeletal myotoxicity from simvastatin and colchicine","volume":"30","author":"Baker","year":"2004","journal-title":"Muscle and Nerve"},{"issue":"1","key":"10.1016\/j.ahj.2019.09.011_bb0270","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clinthera.2018.09.011","article-title":"Colchicine in stable coronary artery disease","volume":"41","author":"Fiolet","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.ahj.2019.09.011_bb0275","unstructured":"ClinicalTrials.gov. Colchicine Cardiovascular Outcomes Trial (COLCOT). NCT02551094. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02551094. Published 2015. Accessed August 15, 2019."},{"key":"10.1016\/j.ahj.2019.09.011_bb0280","unstructured":"ClinicalTrials.gov. Colchicine and Spironolactone in Patients With STEMI \/ SYNERGY Stent Registry (CLEAR-SYNERGY). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03048825. Published 2017. Accessed August 15, 2019."},{"key":"10.1016\/j.ahj.2019.09.011_bb0285","unstructured":"ClinicalTrials.gov. Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke (CONVINCE). NCT02898610."},{"issue":"5","key":"10.1016\/j.ahj.2019.09.011_bb0290","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ni.2550","article-title":"Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome","volume":"14","author":"Misawa","year":"2013","journal-title":"Nat Immunol"},{"issue":"7081","key":"10.1016\/j.ahj.2019.09.011_bb0295","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ahj.2019.09.011_bb0310","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/ard.40.6.605","article-title":"Prolonged reduction in polymorphonuclear adhesion following oral colchicine","volume":"40","author":"Fordham","year":"1981","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ahj.2019.09.011_bb0315","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1136\/annrheumdis-2014-205958","article-title":"Neutrophil extracellular traps regulate IL-1\u03b2-mediated inflammation in familial Mediterranean fever","volume":"75","author":"Apostolidou","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ahj.2019.09.011_bb0320","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11239-011-0637-y","article-title":"Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: A pilot randomized controlled trial","volume":"33","author":"Raju","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.ahj.2019.09.011_bb0330","unstructured":"ClinicalTrials.gov. COACS colchicine for acute coronary syndromes; NCT01906749. 2013. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01906749. Accessed August 15, 2019."},{"key":"10.1016\/j.ahj.2019.09.011_bb0335","unstructured":"ClinicalTrials.gov. Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke (CONVINCE). NCT02898610. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02898610. Published 2016. Accessed August 15, 2019."}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319302698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319302698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:14:33Z","timestamp":1777378473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870319302698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":64,"alternative-id":["S0002870319302698"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2019.09.011","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2019.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}